Find this video on youtube
Source links:
What’s Next For COVID Vaccines With Tonix Pharmaceuticals’ Seth Lederman, M.D.
Tonix Pharmaceuticals’ CEO Reveals Next-Generation COVID Vaccine Technology chosen for key program
Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
Tonix Pharmaceuticals pipeline
Project NextGen Enhancing Preparedness for Future COVID-19 Strains & Variants with Next Generation Medical Countermeasures
Project NextGen Selects Initial Vaccine Candidates and Awards Over $500 Million to Advance Development of Vaccines and Therapeutics
Project NextGen: Director Robert Johnson Introduction